Vivek Subbiah about “Tumor-Agnostic Biomarker Driven Drug development” at ASCO and ESMO joint session

Vivek Subbiah shared a post on LinkedIn:

“It was such a great honor to talk about “Tumor-Agnostic Biomarker Driven Drug development: How & How often?” at the special joint session of American Society of Clinical Oncology (ASCO) & ESMO – European Society for Medical Oncology meeting!

Grateful to our beloved ASCO President & amazing ESMO President for the invite to the talk & their vision in putting this amazing session together.

Link to the Annals of Oncology Annals of Oncology ETAC-S paper.”

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development

Authors: C.B. Westphalen, et al.

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.